A cost-effectiveness analysis of a vaccination program against Haemophilus influenzae type b (Hib) was conducted using French epidemiological data.
The vaccine would be added as a fifth valence to the tetravalent vaccines (DTCP) widely used in France.
The permanent sequelae of the Hib invasive diseases which might be avoided by vaccination were weighted to determine Quality Adjusted Life Years gained.
In a stable French population of3 746000 children aged<5 years old (1990), and for a followup period often years, the cost-effectiveness ratio of such a program for the French national health insurance system would equal 54084 FF per year of life added or 34050 FF per QALY.
The net cost of the program during that period would be 1.02 billion FFfor the French national health insurance system and 920 million FF for patients'families.
Comparison of these projections with available information supports, a posteriori, the decision of the French government to authorize the licensing of the pentavalent vaccine.
Mots-clés Pascal : Haemophilus influenzae, Pasteurellaceae, Bactérie, Bactériose, Infection, Immunoprophylaxie, Vaccination, Nourrisson, Homme, Vaccin associé, Vaccin bivalent, Analyse avantage coût, France, Europe, Prévention
Mots-clés Pascal anglais : Haemophilus influenzae, Pasteurellaceae, Bacteria, Bacteriosis, Infection, Immunoprophylaxis, Vaccination, Infant, Human, Mixed vaccine, Bivalent vaccine, Cost benefit analysis, France, Europe, Prevention
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0283015
Code Inist : 002A05B12. Création : 199608.